Core Insights - Corcept Therapeutics Incorporated is under investigation by Bernstein Liebhard LLP for potential violations of federal securities laws [1][2] - The company received a Complete Response Letter from the FDA regarding its New Drug Application for relacorilant, which led to a significant drop in its stock price [3] Company Developments - On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter for relacorilant, indicating that while the pivotal GRACE trial met its primary endpoint, additional evidence of effectiveness is required for a favorable benefit-risk assessment [3] - Following the FDA's announcement, Corcept's stock price fell by $35.40 per share, representing a 50.42% decline, closing at $34.80 per share [3] Legal Context - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success, indicating a strong capability in handling investor rights cases [4]

Group 1 - Freeport-McMoRan (FCX) is a leading mining company with significant copper and gold production, currently facing legal challenges but showing stock resilience [1][2][5] - RBC Capital has set a price target of $48 for FCX, indicating a potential upside of 22.39% from its current trading price of $39.22 [1][5] - The Rosen Law Firm is investigating potential securities claims against FCX due to allegations of misleading business information [2][5] Group 2 - FCX's stock price has increased by 5.66%, reflecting market resilience despite ongoing legal issues [3][5] - The company's market capitalization is approximately $56.31 billion, indicating its significant presence in the mining industry [4] - The trading volume for FCX on the day is 38.54 million shares, suggesting active investor engagement [4]